Clinical recovery from surgery correlates with single-cell immune signatures

Science Translational Medicine, Journal Year: 2014, Volume and Issue: 6(255)

Published: Sept. 24, 2014

Single-cell mass cytometry revealed immune correlates of patient-associated variability in surgical recovery.

Language: Английский

---

Scaling by shrinking: empowering single-cell 'omics' with microfluidic devices

Nature Reviews Genetics, Journal Year: 2017, Volume and Issue: 18(6), P. 345 - 361

Published: April 10, 2017

Language: Английский

---

Combinatorial tetramer staining and mass cytometry analysis facilitate T-cell epitope mapping and characterization

Nature Biotechnology, Journal Year: 2013, Volume and Issue: 31(7), P. 623 - 629

Published: June 9, 2013

Language: Английский

---

JAK–STAT Pathway Activation in Malignant and Nonmalignant Cells Contributes to MPN Pathogenesis and Therapeutic Response

Cancer Discovery, Journal Year: 2015, Volume and Issue: 5(3), P. 316 - 331

Published: Jan. 9, 2015

Abstract The identification of JAK2/MPL mutations in patients with myeloproliferative neoplasms (MPN) has led to the clinical development JAK kinase inhibitors, including ruxolitinib. Ruxolitinib reduces splenomegaly and systemic symptoms myelofibrosis improves overall survival; however, mechanism by which inhibitors achieve efficacy not been delineated. Patients MPN present increased levels circulating proinflammatory cytokines, are mitigated inhibitor therapy. We sought elucidate mechanisms attenuate cytokine-mediated pathophysiology. Single-cell profiling demonstrated that hematopoietic cells from models patient samples aberrantly secrete inflammatory cytokines. Pan-hematopoietic Stat3 deletion reduced disease severity attenuated cytokine secretion, similar as observed ruxolitinib In contrast, restricted did reduce or production. Consistent these observations, we found malignant nonmalignant cytokines inhibition production both populations. Significance: Our results demonstrate JAK–STAT3-mediated contributes pathogenesis populations is required for therapeutic efficacy. These findings provide novel insight into achieves MPNs. Cancer Discov; 5(3); 316–31. ©2015 AACR. See related commentary Belver Ferrando, p. 234 This article highlighted Issue feature, 213

Language: Английский

---

The use of skin models in drug development

Advanced Drug Delivery Reviews, Journal Year: 2014, Volume and Issue: 69-70, P. 81 - 102

Published: Jan. 3, 2014

Language: Английский

---